Pioneering the future of skin diagnostics
On the back of its innovative skin cancer detection device, Nevisense, SciBase has experienced significant revenue growth in recent years. With the company currently expanding into the US market, we find the potential for even higher revenue growth credible. However, the company has yet to turn a profit and has been, and likely continues to be, reliant on equity offerings to fund its operations. In addition, visibility into the complex US healthcare industry is poor, which makes predicting the timing of cash flow positivity an uncertain prospect. Therefore, while we have a strong positive outlook for the Nevisense device and anticipate high revenue growth, the above factors lead us to consider the share appropriately priced in the near term
Login required
This content is only available for logged in users
Scibase Holding
SciBase Holding is a medical technology company. The Group specializes in the management of cancer diagnostics, mainly focused on the treatment and detection of various melanomas. The company has developed an electric handheld probe that analyzes the measurement signal to detect specific changes in the body's skin tissue. The head office is located in Stockholm.
Read more on company pageKey Estimate Figures01.02.
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 17.9 | 23.7 | 33.8 |
growth-% | 52.55 % | 32.61 % | 42.57 % |
EBIT (adj.) | -46.4 | -51.3 | -51.0 |
EBIT-% (adj.) | -259.47 % | -216.26 % | -150.84 % |
EPS (adj.) | -0.63 | -0.45 | -0.43 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |